In August 2025, Hoffmann-La Roche announced a study is to compare the efficacy and safety of glofitamab in combination with ...

Shares of Fortinet were down as much as 27.4% in Thursday action, which would have made for their worst performance on record, though they ended down 22%. That finish marked the stock's steepest ...